Harish SHARMA, Gyanesh Kumar SAHU, Swarnali Das PAUL, Chanchal Deep KAUR

Comparative Study of Marketed and Novel Colloidal Formulation for Topical Delivery of 5-Fluorouracil to Skin Cancer Cells: Ex-Vivo Release Study and Cytotoxicity Analysis

OBJECTIVE The objective of the present work was to compare the efficacy of two formulations (microemulsion [ME] and nanoemulsion [NE]) with marketed product on skin cancer cell lines. METHODS For this purpose, we studied two parameters, that is, drug release both in ex vivo conditions and cyto- toxicity profile. For ex vivo skin permeability studies skin of male Sprague Dawley rats, goats, and hu- man cadaver was selected. For in vitro cytotoxicity study, SK-MEL-5 melanoma cell lines were used. % cell death was concentration dependent. RESULTS The highest concentration (96 μM) maximum cell death was found. The nanoemusion had highest inhibi- tory effect in any concentration than control or ME. Similar results were obtained for permeation study. NE had better permeation property than other. CONCLUSION Based on the permeation results, we found that highest amount of 5-fluorouracil collected in the viable part of the human cadaver and goat skin model from NE as compared to other preparations. Finally, it can be concluded that NE of the model drug had better properties in cytotoxicity and skin permeation than marketed topical product.

PDF

___

1. Rajinikanth PS, Chellian J. Development and evalua- tion of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine 2016;11:5067–77.
2. Van Ruth S, Jansman FGA, Sanders CJ. Total body top- ical 5-fluorouracil for extensive non-melanoma skin cancer. Pharm World Sci 2006;28(3):159–62.
3. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacoki- netically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009;101(22):1543–52.
4. Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats. J Invest Dermatol. 2007;127(1):154–62.
5. Elmeshad AN, Tadros MI. Transdermal delivery of an anti-cancer drug via W/O emulsions based on alkyl polyglycosides and lecithin: Design, characterization, and in vivo evaluation of the possible irritation poten- tial in rats. AAPS PharmSciTech. 2011;12(1):1–9.
6. Liu F, Xiao YY, Ping QN, Yang C. Water in oil mi- croemulsions for transdermal delivery of fluorouracil. Yaoxue Xuebao 2009;44(5):540–7.
7. Chinembiri TN, Gerber M, du Plessis L, du Preez J, du Plessis J. Topical delivery of 5-fluorouracil from PheroidTM formulations and the in vitro efficacy against human melanoma. AAPS PharmSciTech 2015;16(6):1390–9.
8. Patzelt A, Antoniou C, Sterry W, Lademann J. Skin penetration from the inside to the outside: A review. Drug Discov Today Dis Mech 2008;5(2):229–35.
9. Thakur R, Anwer MK, Shams MS, Ali A, Khar RK, Shakeel F, Taha EI. Proniosomal transdermal thera- peutic system of losartan potassium: Development and pharmacokinetic evaluation. J Drug Target 2009;17(6):442–9.